DKK488.40
1.22% yesterday
Copenhagen, Jun 19, 04:59 pm CET
ISIN
DK0062498333
Symbol
NOVO B
Sector
Industry

Novo Nordisk Stock price

DKK488.40
+49.70 11.33% 1M
-254.80 34.28% 6M
-135.80 21.76% YTD
-495.80 50.38% 1Y
+263.75 117.40% 5Y
+307.05 169.31% 10Y
+457.55 1,483.14% 20Y
Copenhagen, Closing price Thu, Jun 19 2025
+5.90 1.22%
ISIN
DK0062498333
Symbol
NOVO B
Sector
Industry

Key metrics

Market capitalization DKK2.14t
Enterprise Value DKK2.22t
P/E (TTM) P/E ratio 20.77
EV/FCF (TTM) EV/FCF 29.84
EV/Sales (TTM) EV/Sales 7.32
P/S ratio (TTM) P/S ratio 7.07
P/B ratio (TTM) P/B ratio 15.65
Dividend yield 2.33%
Last dividend (FY24) DKK11.40
Revenue growth (TTM) Revenue growth 24.11%
Revenue (TTM) Revenue DKK303.14b
EBIT (operating result TTM) EBIT DKK135.28b
Free Cash Flow (TTM) Free Cash Flow DKK74.36b
Cash position DKK41.55b
EPS (TTM) EPS DKK23.52
P/E forward 18.50
P/S forward 6.44
EV/Sales forward 6.67
Show more

Is Novo Nordisk a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,872 stocks worldwide.

Novo Nordisk Stock Analysis

Unlock Scores for Free

Analyst Opinions

31 Analysts have issued a Novo Nordisk forecast:

19x Buy
61%
9x Hold
29%
3x Sell
10%

Analyst Opinions

31 Analysts have issued a Novo Nordisk forecast:

Buy
61%
Hold
29%
Sell
10%

Financial data from Novo Nordisk

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
303,141 303,141
24% 24%
100%
- Direct Costs 47,496 47,496
27% 27%
16%
255,645 255,645
24% 24%
84%
- Selling and Administrative Expenses 69,076 69,076
10% 10%
23%
- Research and Development Expense 44,064 44,064
28% 28%
15%
155,307 155,307
29% 29%
51%
- Depreciation and Amortization 20,023 20,023
89% 89%
7%
EBIT (Operating Income) EBIT 135,284 135,284
24% 24%
45%
Net Profit 104,615 104,615
17% 17%
35%

In millions DKK.

Don't miss a Thing! We will send you all news about Novo Nordisk directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Novo Nordisk Stock News

AD HOC NEWS
7 days ago
Aktien von Novo Nordisk DK0062498333 haben am Freitag im Vormittagshandel gegen den Markt zulegt.
AD HOC NEWS
10 days ago
Die Aktien von Novo Nordisk DK0062498333 haben am Dienstag ihre Klettertour fortgesetzt.
AD HOC NEWS
about one month ago
Deutsche Bank Research hat die Einstufung für Novo Nordisk DK0062498333 nach der Ankündigung eines Chefwechsels auf "Buy" mit einem Kursziel von 750 dänischen Kronen belassen.
More Novo Nordisk News

Company Profile

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Head office Denmark
CEO Lars Jørgensen
Employees 76,826
Founded 1931
Website www.novonordisk.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today